Information  X 
Enter a valid email address

Zotefoams PLC (ZTF)

  Print      Mail a friend       Annual reports

Tuesday 28 April, 2020

Zotefoams PLC

Disclosure of rights attached to equity shares

RNS Number : 2185L
Zotefoams PLC
28 April 2020
 

Zotefoams plc

(the 'Company')

 

Document regarding rights attached to equity shares

In compliance with Listing Rule 9.2.6ER(1)(b), the Company has submitted to the National Storage Mechanism a copy of its Articles, which set out, amongst other things, the rights attached to its equity shares.

The document is available for inspection at

https://data.fca.org.uk/#/nsm/nationalstoragemechanism

 

Lydia Harratt

Group Company Secretary

Zotefoams plc

020 8664 1600

 

28 April 2020

 

About Zotefoams plc: 

 

About Zotefoams plc

Zotefoams plc (LSE - ZTF) is a world leader in cellular materials technology.  Utilising a variety of unique manufacturing processes, including environmentally friendly nitrogen expansion for lightweight AZOTE® polyolefin and ZOTEK® high-performance foams, Zotefoams sells to diverse markets worldwide. Zotefoams uses its own cellular materials to manufacture T-FIT® advanced insulation for demanding industrial markets.  In addition, Zotefoams owns and licenses patented microcellular foam technology, developed specifically for extrusion applications, from a base in Massachusetts, USA to customers worldwide.

Zotefoams is headquartered in Croydon, UK, with additional manufacturing sites in Kentucky and Oklahoma, USA (foam products manufacture and conversion), Massachusetts, USA (MuCell Extrusion) and Jiangsu Province, China (T-FIT®). A third foam-manufacturing site, in Poland, is planned to begin operations in 2020.

 

AZOTE®, ZOTEK® and T-FIT® are registered trademarks of Zotefoams plc

www.zotefoams.com


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
CIRIPMATMTJTBRM

a d v e r t i s e m e n t